New drug duo aims to shrink hard-to-treat tumors
NCT ID NCT07469774
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can we predict chemo brain before it happens?